Here are three notes:
1. Needham & Company also raised CONMED’s price target to $52.
2. Needham & Company analyst Mike Matson noted that the company’s new management, sales incentive changes, sales force hires and new products will help “drive revenue growth into the mid-single digits or better over the next two years” and he expects this to “drive EBITDA and multiple expansion.”
3. CONMED shares closed at $46.06 on May 1.
More articles on devices:
Anika Therapeutics’ total revenue up 44% to $22.3M — 5 things to know
Zimmer Biomet, NuVasive, Wenzel Spine & more: 21 key notes
Stryker to launch Tritanium Posterior Lumbar Cage: 4 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
